Acta Pharmaceutica Sinica B · 2016 · 36 citations · 17 references
Life SciencesImmunologyPharmacologyAutoimmunityImmunopathologyInflammationAutoimmune DiseasesAutoimmune Rheumatic DiseasesImmune-mediated Renal DiseaseRenal DiseaseRenal PharmacologySystemic Lupus ErythematosusHistopathological EffectsIntraperitoneal AdministrationPositive ControlsPristaneRenal Tissue InjurySystemic Lupus Erythematosus ModelsWestern Blot Analysis
The purpose of this study was to investigate the effects of salvianolic acid A (SAA) in systemic lupus erythematosus (SLE) induced by pristane in BALB/c mice. Lupus mice were established by confirming elevated levels of autoantibodies and IL-6 after intraperitoneal injection of pristane. Mice were then treated with daily oral doses of SAA for 5 months in parallel with mice treated with prednisone and aspirin as positive controls. The levels of autoantibodies were monitored at monthly intervals and nephritic symptoms observed by hematoxylin and eosin (H&E) and periodic acid–Schiff (PAS) staining. Western blot analysis of renal tissue was also employed. SAA treatment caused a significant reduction in the levels of anti-Sm autoantibodies and reduced renal histopathological changes and pathological effects. SAA treatment also significantly inhibited the phosphorylation of IKK, IκB and NFκB in renal tissues of lupus mice. In conclusion, the results suggest that SAA alleviates renal injury in pristane-induced SLE in BALB/c mice through inhibition of phosphorylation of IKK, IκB and NFκB.
17
Prognostic factors in lupus nephritis
Howard A. Austin, Larry R. Muenz, Kathleen Joyce et al. · The American Journal of Medicine · 1983 · 772 citations
Prognostic factors in lupus nephritis
Chi Chiu Mok · Lupus · 2005 · 119 citations
Jun Xie, Jiahui Liu, Heng Liu et al. · Acta Pharmaceutica Sinica B · 2015 · 113 citations · Full text